HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stability of improvements in exercise performance and quality of life following bilateral lung volume reduction surgery in severe COPD.

AbstractSTUDY OBJECTIVE:
To evaluate the long-term stability of improvements in exercise capacity and quality of life (QOL) after lung volume reduction surgery (LVRS).
DESIGN:
Case-series analysis.
SETTING:
University hospital.
PATIENTS:
Twenty-six patients with severe airflow obstruction (mean FEV1 of 0.67+/-0.18 L) and moderate to severe hyperinflation (mean total lung capacity of 7.30+/-1.90 L).
INTERVENTION AND MEASUREMENTS:
All patients underwent bilateral LVRS via median sternotomy. Serial measurement of lung function, symptom-limited cardiopulmonary exercise tests, 6-min walk distances (6MWD), and sickness impact profile (SIP) scores were done before, and at 3, 6, 12, and 18 months after surgery.
RESULTS:
FEV1 (0.93+/-0.29 vs 0.68+/-0.19 L, p<0.001) increased while residual volume (3.47+/-1.2 vs 4.77+/-1.5 L, p<0.001) decreased significantly at 3 months post-LVRS compared to baseline, and these changes were maintained at 12 to 18 months follow-up. Similarly, the increase in 6MWD at 3 months post-LVRS (340+/-84 vs 251+/-114 m, p<0.001) was sustained at all follow-up times. On cardiopulmonary exercise testing, total exercise time (9.0+/-1.8 vs 6.1+/-1.9 min, p<0.001), oxygen uptake at peak exercise (VO2 peak) (14.9+/-4 vs 11.9+/-3 mL/kg/min, p<0.001), maximum oxygen pulse (7.43+/-2.37 vs 5.85+/-1.96 mL/beat, p<0.005), and maximum minute ventilation (VEmax) (30.3+/-10 vs 23.5+/-7.1 L/min, p<0.001) increased significantly at 3 months post-LVRS. On serial study following LVRS, total exercise time remained significantly greater at 6 (8.5+/-1.38 min) and 12 months (8.71+/-2.0 min) post-LVRS compared to baseline (5.81+/-1.9 min, p<0.05). VO2 peak tended to be higher at all follow-up periods (3 months, 16.1+/-4.3; 6 months, 14.5+/-2.6; 12 months, 14.1+/-3.5 mL/kg) compared to baseline (12.6+/-3.9 mL/kg, p=0.08). Similarly, maximum O2 pulse tended to be higher in all follow-up studies (3 months, 8.45+/-2.7; 6 months, 7.6+/-1.7; 12 months, 7.42+/-2.1 mL/beat) compared to baseline (6.39+/-2.5 mL/beat, p=0.06). Higher VEmax continued to be observed at 6 (30+/-10 L/min) and 12 months (28+/-10 L/min) post-LVRS, compared to baseline (23+/-7 L/min, p=0.02). VEmax post-LVRS was significantly higher at 3 and 6 months compared to baseline on post-hoc analysis (p<0.05). Overall SIP scores were lower at 3 months (7 vs 18, p<0.0002) post-LVRS and were sustained in long-term follow-up.
CONCLUSION:
We conclude that bilateral LVRS via median sternotomy in selected patients with severe, diffuse emphysema improves exercise performance and QOL at 3 months following LVRS and these improvements are maintained for at least 12 to 18 months in follow-up.
AuthorsF Cordova, G O'Brien, S Furukawa, A M Kuzma, J Travaline, G J Criner
JournalChest (Chest) Vol. 112 Issue 4 Pg. 907-15 (Oct 1997) ISSN: 0012-3692 [Print] United States
PMID9377952 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Oxygen
Topics
  • Airway Obstruction (physiopathology, psychology, surgery)
  • Exercise Test
  • Exercise Tolerance
  • Female
  • Follow-Up Studies
  • Forced Expiratory Volume (physiology)
  • Humans
  • Longitudinal Studies
  • Lung (physiopathology)
  • Lung Compliance (physiology)
  • Male
  • Maximal Voluntary Ventilation (physiology)
  • Middle Aged
  • Oxygen (blood)
  • Oxygen Consumption (physiology)
  • Physical Exertion (physiology)
  • Pneumonectomy (methods)
  • Pulmonary Emphysema (physiopathology, psychology, surgery)
  • Pulmonary Gas Exchange (physiology)
  • Quality of Life
  • Residual Volume (physiology)
  • Sickness Impact Profile
  • Spirometry
  • Sternum (surgery)
  • Thoracotomy
  • Total Lung Capacity (physiology)
  • Walking (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: